Literature DB >> 11511426

Activation of the cardiac interleukin-6 system in advanced heart failure.

G Plenz1, Z F Song, T D Tjan, C Koenig, H A Baba, M Erren, M Flesch, T Wichter, H H Scheld, M C Deng.   

Abstract

OBJECTIVES: The study objective was to assess the cardiac expression of interleukin-6 (IL6) and its receptor (IL6R) in advanced heart failure.
BACKGROUND: While IL6 plasma levels are elevated and associated with an impaired prognosis in advanced heart failure, little is known about the intracardiac expression of the IL6 system.
METHODS: Heart tissue was obtained from 20 patients (n=10, idiopathic dilated cardiomyopathy, age 44+/-15 years; n=10, ischemic cardiomyopathy, age 55+/-8 years) at the time of transplantation. Left and right ventricular tissue was subjected to in situ hybridization, Northern blot analysis, and RT-PCR. Signals were quantified by densitometric scanning and corrected for G3PDH-mRNA levels. Right ventricular biopsy specimens (n=11) of patients with arrhythmias and normal cardiac function served as controls. In addition, data were correlated with cardiac catheterization and echocardiography data obtained at transplant evaluation.
RESULTS: Ventricular IL6 and IL6R transcripts were detected in all explant specimens examined. Expression of both mRNA species was higher than in controls (P=0.001). Left ventricular IL6 mRNA levels correlated positively with heart rate (r=0.77; P=0.009), pulmonary capillary wedge pressure (r=0.53; P=0.03), right atrial pressure (r=0.77; P=0.003), and inversely with left ventricular ejection fraction (r=-0.61; P=0.03). Right ventricular IL6 mRNA levels correlated inversely with cardiac index (r=-0.48; P=0.05). IL6R expression did not correlate with hemodynamic data.
CONCLUSIONS: In advanced heart failure, cardiac IL6/IL6R mRNA expression is increased and may play a role in the pathophysiology of advanced heart failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511426     DOI: 10.1016/s1388-9842(01)00137-4

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  25 in total

Review 1.  Immune modulation in heart failure: past challenges and future hopes.

Authors:  Jose H Flores-Arredondo; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Curr Heart Fail Rep       Date:  2011-03

2.  Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.

Authors:  Ibrahim Halil Kurt; Kemal Yavuzer; Mustafa Kemal Batur
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

3.  Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy.

Authors:  M Vanderheyden; W J Paulus; M Voss; P Knuefermann; N Sivasubramanian; D Mann; G Baumgarten
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

4.  p21(WAF1/Cip1/Sdi1) knockout mice respond to doxorubicin with reduced cardiotoxicity.

Authors:  Jerome Terrand; Beibei Xu; Steve Morrissy; Thai Nho Dinh; Stuart Williams; Qin M Chen
Journal:  Toxicol Appl Pharmacol       Date:  2011-09-03       Impact factor: 4.219

Review 5.  Reappraisal of Inflammatory Biomarkers in Heart Failure.

Authors:  Thanat Chaikijurajai; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-02

Review 6.  [CARs, CRS and neurotoxicity: severe complications after administration of immunotherapy : Essentials for intensivists].

Authors:  J Prinz; Y d'Hargues; P Gödel; A Shimabukuro-Vornhagen; M Kochanek; B Böll
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-12-13       Impact factor: 0.840

7.  Interleukin 6 regulates psoriasiform inflammation-associated thrombosis.

Authors:  Yunmei Wang; Jackelyn B Golden; Yi Fritz; Xiufen Zhang; Doina Diaconu; Maya I Camhi; Huiyun Gao; Sean M Dawes; Xianying Xing; Santhi K Ganesh; Johann E Gudjonsson; Daniel I Simon; Thomas S McCormick; Nicole L Ward
Journal:  JCI Insight       Date:  2016-12-08

Review 8.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

9.  Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody.

Authors:  Junya Kanda; Hiroshi Kawabata; Yuhei Yamaji; Tatsuo Ichinohe; Takayuki Ishikawa; Toshihiro Tamura; Yutaka Furukawa; Takeshi Kimura; Toru Kita; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

10.  [Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure].

Authors:  K Lenz; A Gegenhuber; F Firlinger; G Lohr; P Piringer
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-19       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.